- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
120: The New Normal?
Podcast: Hypertension expert Daichi Shimbo, MD, offers tips on putting SPRINT results into clinical practice.
According to newly published data from the SPRINT study, 120 mm Hg may be the new normal blood pressure for a large group of people. But it’s hard enough getting most people to 140.
In this podcast, hypertension expert Dr. Daichi Shimbo provides a brief overview of that landmark study-and offers some tips about how you can help select patients achieve this new normal.
Dr. Shimbo is Associate Professor of Medicine, Columbia University; Director, Laboratory at the Center for Behavioral Cardiovascular Health; Director, Cardiovascular Physiology Research, Cardiovascular Ultrasound Laboratories; and Ewig Clinical Scholar at Columbia University Medical Center, New York, NY.
For More Information
The SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373:2103-2116.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
